Showing 321 - 340 results of 74,136 for search '(( 50 ((026 decrease) OR (a decrease)) ) OR ( 5 ((mean decrease) OR (we decrease)) ))', query time: 1.05s Refine Results
  1. 321

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
  2. 322
  3. 323

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  4. 324
  5. 325

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  6. 326
  7. 327
  8. 328

    Sarcopenia as an Independent Risk Factor for Decreased BMD in COPD Patients: Korean National Health and Nutrition Examination Surveys IV and V (2008-2011) by Dong-Won Lee (2208223)

    Published 2016
    “…<div><p>Background</p><p>A decrease in bone mineral density (BMD) is a systemic consequence of chronic obstructive pulmonary disease (COPD). …”
  9. 329
  10. 330
  11. 331

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339
  20. 340